Impairing MLL-fusion gene-mediated transformation by dissecting critical interactions with the lens epithelium-derived growth factor (LEDGF/p75).

abstract：:In this open-label randomized clinical trial, HLA-identical sibling-matched hematopoietic stem cells (HSC) were transplanted (non-MSCs group, n=15) or cotransplanted with mesenchymal stem cells (MSCs) (MSCs group, n=10) in hematologic malignancy patients. The median number of MSCs infused was 3.4 x 10(5) kg(-1) (range...

journal_title：Leukemia

authors： Ning H,Yang F,Jiang M,Hu L,Feng K,Zhang J,Yu Z,Li B,Xu C,Li Y,Wang J,Hu J,Lou X,Chen H

更新日期：2008-03-01 00:00:00

abstract：:The pharmacology of ID and IDOL are of interest in light of the potential utility of ID in the treatment of adult and pediatric leukemia patients. Preclinical activity and cellular pharmacology of ID were suggestive of greater clinical activity when compared with several standard anthracyclines. Most intriguing were d...

journal_title：Leukemia

authors： Ames MM,Spreafico F

更新日期：1992-01-01 00:00:00

abstract：:Myeloproliferative neoplasms with myelofibrosis (MPN-MF) demonstrate constitutive activation of Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling that responds to treatment with the JAK1 and 2 kinase inhibitor (JAKi) ruxolitinib. However, MPN-MF often progresses (~20%) to secondary acu...

journal_title：Leukemia

authors： Saenz DT,Fiskus W,Manshouri T,Rajapakshe K,Krieger S,Sun B,Mill CP,DiNardo C,Pemmaraju N,Kadia T,Parmar S,Sharma S,Coarfa C,Qiu P,Verstovsek S,Bhalla KN

更新日期：2017-03-01 00:00:00

abstract：:Bruton's tyrosine kinase (BTK) inhibitor is a promising novel agent that has potential efficiency in B-cell malignancies. It took approximately 20 years from target discovery to new drug approval. The first-in-class drug ibrutinib creates possibilities for an era of chemotherapy-free management of B-cell malignancies,...

journal_title：Leukemia

authors： Wen T,Wang J,Shi Y,Qian H,Liu P

更新日期：2020-10-29 00:00:00

abstract：:The chimeric fusion oncogene early B-cell factor 1-platelet-derived growth factor receptor-β (EBF1-PDGFRB) is a recurrent lesion observed in Philadelphia-like B-acute lymphoblastic leukemia (B-ALL) and is associated with particularly poor prognosis. While it is understood that this fusion activates tyrosine kinase sig...

journal_title：Leukemia

authors： Welsh SJ,Churchman ML,Togni M,Mullighan CG,Hagman J

更新日期：2018-01-01 00:00:00

abstract：:Chronic graft-versus-host disease (GVHD) remains a serious complication after allogeneic hematopoietic stem cell transplantation (HCT). In 2005 the National Institutes of Health (NIH) established new criteria for chronic GVHD based on retrospective data and expert recommendations. We prospectively evaluated the incide...

journal_title：Leukemia

authors： Kuzmina Z,Eder S,Böhm A,Pernicka E,Vormittag L,Kalhs P,Petkov V,Stary G,Nepp J,Knobler R,Just U,Krenn K,Worel N,Greinix HT

更新日期：2012-04-01 00:00:00

abstract：:We previously demonstrated that the EVI-1 gene was transcriptionally activated in the 3q21q26 syndrome and chromosomal breakpoints at 3q26 were clustered within 400 Kb of the EVI-1 gene. Since thrombocytosis is often observed in the 3q21q26 syndrome, we first mapped the thrombopoietin (TPO) gene and then we examined f...

journal_title：Leukemia

authors： Suzukawa K,Satoh H,Taniwaki M,Yokota J,Morishita K

更新日期：1995-08-01 00:00:00

abstract：:Identification of agents that target human leukemia stem cells is an important consideration for the development of new therapies. The present study demonstrates that rocaglamide and silvestrol, closely related natural products from the flavagline class of compounds, are able to preferentially kill functionally define...

journal_title：Leukemia

authors： Callahan KP,Minhajuddin M,Corbett C,Lagadinou ED,Rossi RM,Grose V,Balys MM,Pan L,Jacob S,Frontier A,Grever MR,Lucas DM,Kinghorn AD,Liesveld JL,Becker MW,Jordan CT

更新日期：2014-10-01 00:00:00

abstract：:Of 240 Japanese children with acute lymphoblastic leukemia (ALL) treated between 1983 and 1990, 75 (31%) had normal diploidy, 47 (20%) hyperdiploidy with more than 50 chromosomes, 18 (8%) hyperdiploidy with 47-50 chromosomes, 77 (32%) pseudodiploidy, 22 (9%) hypodiploidy and one hypotetraploidy in the leukemic cells. ...

journal_title：Leukemia

authors： Kobayashi H,Maseki N,Homma C,Sakurai M,Kaneko Y

更新日期：1994-11-01 00:00:00

abstract：:We used a modification of the polymerase chain reaction (PCR) to amplify the specific bcr-abl mRNA from 14 patients with chronic myeloid leukemia (CML) who had previously received non T cell depleted allogenic bone marrow transplantation (BMT). Two types of reactions were used: a single step amplification with 5' and ...

journal_title：Leukemia

authors： Delfau MH,Kerckaert JP,Collyn d'Hooghe M,Fenaux P,Laï JL,Jouet JP,Grandchamp B

更新日期：1990-01-01 00:00:00

abstract：:It has become apparent that regulation of protein translation is an important determinant in controlling cell growth and leukemic transformation. The phosphoinositide 3-kinase (PI3K)/phosphatase and tensin homologue deleted on chromosome ten (PTEN)/Akt/mammalian target of rapamycin (mTOR) pathway is often implicated i...

journal_title：Leukemia

authors： Martelli AM,Evangelisti C,Chappell W,Abrams SL,Bäsecke J,Stivala F,Donia M,Fagone P,Nicoletti F,Libra M,Ruvolo V,Ruvolo P,Kempf CR,Steelman LS,McCubrey JA

更新日期：2011-07-01 00:00:00

abstract：:Little is known about the incidence of and risk factor for late effects of infant leukemia. We evaluated 19 children with acute lymphoblastic leukemia and 15 with acute myeloid leukemia who were diagnosed at age 12 months or younger and have survived for more than 5 years after the diagnosis (median length of follow-u...

journal_title：Leukemia

authors： Leung W,Hudson M,Zhu Y,Rivera GK,Ribeiro RC,Sandlund JT,Bowman LC,Evans WE,Kun L,Pui CH

更新日期：2000-07-01 00:00:00

abstract：:Although allogeneic bone marrow transplantation has been shown to be a highly effective treatment for acute and chronic leukemia, leukemic relapse remains a significant problem. Leukemic relapse occurs in recipient cells in the majority of cases, but the paucity of donor cell leukemias may reflect the sensitivity of t...

journal_title：Leukemia

authors： Mc Cann SR,Lawler M,Gardiner N,O'Riordan J,Humphries P,De Arce M

更新日期：1994-04-01 00:00:00

abstract：:Previously, we identified SETD2 loss-of-function mutations in 22% of MLL-rearranged (MLLr) acute leukemia patients, implicating a mechanism for cooperativity between SETD2 mutations and MLL fusions. However, the detailed mechanism of how SETD2-H3K36me3 downregulation accelerates MLLr leukemia remains unclear. Here, we...

journal_title：Leukemia

authors： Bu J,Chen A,Yan X,He F,Dong Y,Zhou Y,He J,Zhan D,Lin P,Hayashi Y,Sun Y,Zhang Y,Xiao Z,Grimes HL,Wang QF,Huang G

更新日期：2018-04-01 00:00:00

abstract：:An increased number of circulating CD34+ hematopoietic progenitors with a prominent proliferation of the megakaryocytic (MK) population are the hallmarks of the myeloproliferation in myelofibrosis with myeloid metaplasia (MMM). Analyzing the potential contribution of the stem cell leukemia (SCL) gene in MMM myeloproli...

journal_title：Leukemia

authors： Steunou V,Le Bousse-Kerdilès MC,Colin-Micouin A,Clay D,Chevillard S,Martyré MC,French INSERM Research Network on Myelofibrosis Myeloid Metaplasia.

更新日期：2003-10-01 00:00:00

abstract：:Proliferation in vitro of the murine hemopoietic cell line FDC-P1 is dependent on stimulation by granulocyte-macrophage colony stimulating factor or multipotential colony stimulating factor. Although immortalized, the cells are not tumorigenic on subcutaneous inoculation. Intravenous injection of FDC-P1 cells into syn...

journal_title：Leukemia

authors： Dührsen U,Metcalf D

更新日期：1988-06-01 00:00:00

abstract：:The impact of ten-eleven-translocation 2 (TET2) mutations on response to azacitidine (AZA) in MDS has not been reported. We sequenced the TET2 gene in 86 MDS and acute myeloid leukemia (AML) with 20-30% blasts treated by AZA, that is disease categories wherein this drug is approved by Food and Drug Administration (FDA...

journal_title：Leukemia

authors： Itzykson R,Kosmider O,Cluzeau T,Mansat-De Mas V,Dreyfus F,Beyne-Rauzy O,Quesnel B,Vey N,Gelsi-Boyer V,Raynaud S,Preudhomme C,Adès L,Fenaux P,Fontenay M,Groupe Francophone des Myelodysplasies (GFM).

更新日期：2011-07-01 00:00:00

abstract：:Oligoclonal B cell proliferation, as defined by the presence of more than one leukemic clone, has been detected in approximately 20% to 30% of patients with acute lymphoblastic leukemia (ALL) using PCR or Southern blotting. An accurate assessment of these populations is required to avoid false negative measurements of...

journal_title：Leukemia

authors： Moreira I,Papaioannou M,Mortuza FY,Gameiro P,Palmisano GL,Harrison CJ,Prentice HG,Mehta AB,Hoffbrand AV,Foroni L

更新日期：2001-10-01 00:00:00

abstract：:One-hundred, twenty-eight patients with Hodgkin's disease in remission or who had failed a mechlorethamine, vincristine, procarbazine and prednisone (MOPP), a doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) and/or lomustine, etoposide and prednimustine (CEP) regimens have been treated with a high-dose thera...

journal_title：Leukemia

authors： Carella Am,Carlier P,Congiu A,Occhini D,Meloni G,Anselmo AP,Mandelli F,Mazza P,Tura S,Mangoni L

更新日期：1991-01-01 00:00:00

abstract：:The majority of chronic phase chronic myeloid leukemia (CML) patients treated with the tyrosine kinase inhibitor (TKI) imatinib mesylate maintain durable responses to the drug. However, most patients relapse after withdrawal of imatinib and advanced stage patients often develop drug resistance. As CML is considered a ...

journal_title：Leukemia

authors： Brendel C,Scharenberg C,Dohse M,Robey RW,Bates SE,Shukla S,Ambudkar SV,Wang Y,Wennemuth G,Burchert A,Boudriot U,Neubauer A

更新日期：2007-06-01 00:00:00

abstract：:Clinical characteristics, treatment response and outcome were evaluated in children with Down's syndrome (DS) and acute lymphoblastic leukemia (ALL) as compared to other children with ALL (NDS). Sixty-one DS and 4049 NDS patients, receiving intensive antileukemic treatment during four consecutive trials (ALL-BFM 81, 8...

journal_title：Leukemia

authors： Dördelmann M,Schrappe M,Reiter A,Zimmermann M,Graf N,Schott G,Lampert F,Harbott J,Niemeyer C,Ritter J,Dörffel W,Nessler G,Kühl J,Riehm H

更新日期：1998-05-01 00:00:00

abstract：:Imatinib is usually a highly effective treatment for myeloproliferative neoplasms (MPNs) associated with ABL, PDGFRA or PDGFRB gene fusions; however, occasional imatinib-responsive patients have been reported without abnormalities of these genes. To identify novel imatinib-sensitive lesions, we screened 11 BCR-ABL-neg...

journal_title：Leukemia

authors： Chase A,Schultheis B,Kreil S,Baxter J,Hidalgo-Curtis C,Jones A,Zhang L,Grand FH,Melo JV,Cross NC

更新日期：2009-02-01 00:00:00

abstract：:The microenvironments of leukemia and cancer are critical for multiple stages of malignancies, and they are an attractive therapeutic target. While skeletal abnormalities are commonly seen in children with acute lymphoblastic leukemia (ALL) prior to initiating osteotoxic therapy, little is known about the alterations ...

journal_title：Leukemia

authors： Cheung LC,Tickner J,Hughes AM,Skut P,Howlett M,Foley B,Oommen J,Wells JE,He B,Singh S,Chua GA,Ford J,Mullighan CG,Kotecha RS,Kees UR

更新日期：2018-11-01 00:00:00

abstract：:Human leukocyte antigens (HLA) class I molecules restrict the interaction between cytotoxic T cells and target cells. Abnormalities in HLA class I antigen expression and/or function may provide tumor cells with a mechanism for escaping immune surveillance and resisting T cell-based immunotherapies. The potential for a...

journal_title：Leukemia

authors： Wetzler M,Baer MR,Stewart SJ,Donohue K,Ford L,Stewart CC,Repasky EA,Ferrone S

更新日期：2001-01-01 00:00:00

abstract：:Targeted therapies are frequently combined with standard cytotoxic drugs to enhance clinical response. Targeting the B-cell lymphoma 2 (BCL-2) family of proteins is an attractive option to combat chemoresistance in leukemia. Preclinical and clinical studies indicate modest single-agent activity with selective BCL-2 in...

journal_title：Leukemia

authors： Teh TC,Nguyen NY,Moujalled DM,Segal D,Pomilio G,Rijal S,Jabbour A,Cummins K,Lackovic K,Blombery P,Thompson E,Ekert PG,Lessene G,Glaser SP,Huang DCS,Roberts AW,Guthridge MA,Wei AH

更新日期：2018-02-01 00:00:00

abstract：:Inhibition of NOTCH1 signaling with gamma-secretase inhibitors (GSIs) has been proposed as a molecularly targeted therapy in T-cell acute lymphoblastic leukemia (T-ALL). However, GSIs seem to have limited antileukemic activity in human T-ALL and are associated with severe gastrointestinal toxicity resulting from inhib...

journal_title：Leukemia

authors： Real PJ,Ferrando AA

更新日期：2009-08-01 00:00:00

abstract：:The transcription factor CCAAT enhancer-binding protein alpha (C/EBPalpha) has an important role in granulopoiesis. The tumor suppressor function of C/EBPalpha is shown by the findings that loss of expression or function of C/EBPalpha in leukemic blasts contributes to a block in myeloid cell differentiation and to leu...

journal_title：Leukemia

authors： Pulikkan JA,Dengler V,Peer Zada AA,Kawasaki A,Geletu M,Pasalic Z,Bohlander SK,Ryo A,Tenen DG,Behre G

更新日期：2010-05-01 00:00:00

abstract：:The hematopoietic system is sustained by a rare population of hematopoietic stem cells (HSCs), which emerge during early embryonic development and then reside in the hypoxic niche of the adult bone marrow microenvironment. Although leptin receptor (Lepr)-expressing stromal cells are well-studied as critical regulators...

journal_title：Leukemia

authors： Trinh T,Ropa J,Aljoufi A,Cooper S,Sinn A,Srour EF,Broxmeyer HE

更新日期：2020-11-07 00:00:00

abstract：:The fms-related tyrosine kinase 3 (FLT3) receptor has been extensively studied over the past two decades with regard to oncogenic alterations that do not only serve as prognostic markers but also as therapeutic targets in acute myeloid leukemia (AML). Internal tandem duplications (ITDs) became of special interest in t...

journal_title：Leukemia

authors： Reiter K,Polzer H,Krupka C,Maiser A,Vick B,Rothenberg-Thurley M,Metzeler KH,Dörfel D,Salih HR,Jung G,Nößner E,Jeremias I,Hiddemann W,Leonhardt H,Spiekermann K,Subklewe M,Greif PA

更新日期：2018-02-01 00:00:00

abstract：:The inhibition of nuclear factor kappa B (NF-kappaB) by, for instance, curcumin is becoming an important new approach in combination with chemotherapy or irradiation for the treatment of a variety of cancers including haematological malignancies. A dose-limiting side effect of anticancer therapy in the gastrointestina...

journal_title：Leukemia

authors： van't Land B,Blijlevens NM,Marteijn J,Timal S,Donnelly JP,de Witte TJ,M'Rabet L

更新日期：2004-02-01 00:00:00